NasdaqGM:GPCRPharmaceuticals
Did New Shelf Registration and Oral GLP-1 Progress Just Shift Structure Therapeutics' (GPCR) Investment Narrative?
Structure Therapeutics Inc. recently filed a US$235.64 million shelf registration for 3,541,890 American Depositary Shares tied to its employee stock ownership plan, following earlier Phase 2 data showing significant weight loss with its oral GLP-1 candidate aleniglipron.
These capital markets moves come on the heels of a large hedge fund increasing its position and a very large public offering, underscoring institutional interest in the company’s obesity-focused pipeline.
Against this...